Seminars in Oncology
Volume 35, Issue 5 , Pages 484-493 , October 2008

Progress in Childhood Cancer: 50 Years of Research Collaboration, a Report From the Children's Oncology Group

References 

  1. Children's Oncology Group. Internal documents.
  2. Burchenal JH, Lester RA, Riley JB, et al. Studies on the chemotherapy of leukemia. Cancer. 1948;1:399–412
  3. Farber S, Diamond LK, Mercer RD, et al. Temporary remissions in acute leukemia in children produced by folic acid antagonists, 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med. 1948;238:787
  4. Pearson OH, Eliel LP. Use of adrenocorticotropic hormone (ACTH) and cortisone in lymphomas and leukemias. JAMA. 1950;144:1349
  5. Burchenal JH, Murphy ML, Ellison RR, et al. Clinical evaluation of a new anti-metabolite, 6-mercapto purine in the treatment of leukemia and allied diseases. Blood. 1953;8:965–999
  6. Heyn RM, Brubaker CA, Burchenal JH, et al. The comparison of 6-mercaptopurine with the combination of 6-mercaptopurine and azaserine in the treatment of acute leukemia in children: results of a cooperative study. Blood. 1960;15:350–359
  7. Sitarz A, Heyn R, Murphy ML, et al. Triple drug therapy with actinomycin-D (NSC 3053), chlorambucil (NSC 3088) and methotrexate (NSC 740) in metastatic solid tumors in children. Cancer Chemother Rep. 1965;45:45
  8. Wolff JA, Brubaker CA, Murphy ML, et al. Maintenance of prednisone induced remissions of acute childhood leukemia by thiopurines.
  9. Krivit W, Brubaker C, Hartmann JR, et al. Cyclic vs. sequential use of chemotherapeutic agents in acute leukemia of childhood. [abstract] 1966;Proceedings of the American Association of Cancer Research 57th Annual Meeting, Denver, CO
  10. Leikin SL, Brubaker C, Hartmann JR, et al. Varying Prednisone dosage in remission induction of previously untreated childhood leukemia. Cancer. 1968;21:346–351
  11. Wolff JA, Krivit W, Newton WA, et al. Single versus multiple dose dactinomycin therapy of Wilms' tumor. N Engl J Med. 1968;279:290–294
  12. D'Angio GJ, Evans AE, Breslow N, et al. The treatment of Wilms' tumor: results of the National Wilms' Tumor Study. Cancer. 1976;38:633–646
  13. D'Angio GJ, Evans A, Breslow N, et al. The treatment of Wilms' tumor: results of the second National Wilms' Tumor Study. Cancer. 1981;47:2302
  14. D'Angio GJ, Breslow N, Beckwith JB, et al. The treatment of Wilms' tumor (Results of the Third National Wilms' Tumor Study). Cancer. 1989;64:349–360
  15. Green D, Breslow N, Beckwith J, et al. The effect of duration of treatment on outcome and cost of the treatment for Wilms' Tumor (A report from the National Wilms' Tumor Study Group). J Clin Oncol. 1998;16:3744–3751
  16. Green D, Breslow N, Beckwith J, et al. A comparison between single dose and divided dose administration of dactinomycin and doxorubicin (A report from the National Wilms' Tumor Study Group). J Clin Oncol. 1998;16:237–244
  17. Evans AE, Nrokool P, Evan I, et al. Late effects of treatment for Wilms' tumor (A report from the National Wilms' Tumor Study Group). Cancer. 1991;67:331–336
  18. Grundy PE, Breslow NE, Li S, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol. 2005;23:7312–7321
  19. Beckwith JB, Palmer N. Histopathology and prognosis of Wilms' tumor: results of the National Wilms' Tumor Study. Cancer. 1978;41:1937
  20. Pierce MI, Borges WH, Heyn RM, et al. Epidemiologic factors and survival experience in 1770 children with acute leukemia. Cancer. 1969;23:1296–1304
  21. Nesbit M, Chard R, Evans A, et al. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol. 1979;1:9–13
  22. Heyn R, Holland R. Treatment of rhabdomyosarcoma in children. [abstract] Proc Am Assoc Cancer Res. 1970;2:36
  23. Mauer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study-I: a final report. Cancer. 1988;61:209–220
  24. Maurer HM, Gehan EA, Beltangady M, et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer. 1993;71:1904–1922
  25. Crist WM, Garnsey L, Beltangady MS, et al. Prognosis in children with rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Studies I and II (Intergroup Rhabdomyosarcoma Committee). J Clin Oncol. 1990;8:443–452
  26. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995;13:610–630
  27. Crist WM, Anderson JR, Meza JL, et al. Intergroup Rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease. J Clin Oncol. 2001;19:3091–3102
  28. Donaldson SS, Meza J, Breneman JC, et al. Results from the IRS-IV randomized trial of hyper fractionated radiotherapy in children with rhabdomyosarcoma—a report from the IRSG. Int J Radiat Oncol Biol Phys. 2001;51:718–728
  29. Nesbit ME, Gehan EA, Burgert EO, et al. Multimodal therapy for the management of primary, non-metastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup Study. J Clin Oncol. 1990;8:1664–1674
  30. Razek A, Perez CA, Tefft M, et al. Intergroup Ewing's Sarcoma Study: local control related to radiation dose, volume and site of primary lesion in Ewing's sarcoma. Cancer. 1980;46:516–521
  31. Perez CA, Tefft M, Nesbit ME, et al. Radiation therapy in the multimodal management of Ewing's sarcoma of bone: report of the Intergroup Ewing's Sarcoma Study. Natl Cancer Inst Monogr. 1981;263–271
  32. Burgert EO, Nesbit ME, Garnsey LA, et al. Multimodal therapy for the management of nonpelvic, localized Ewing's Sarcoma of bone: intergroup study IESS-II. J Clin Oncol. 1990;8:1514–1524
  33. Brodeur GM, Seeger RC, Barrett A, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol. 1988;6:1874–1881
  34. Camitta B, Leventhal B, Lauer S, et al. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study. J Clin Oncol. 1989;7:1539–1544
  35. Crist W, Carroll A, Shuster J, et al. Philadelphia chromosome positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome (A Pediatric Oncology Group study). Blood. 1990;76:489–494
  36. Jackson JF, Boyett J, Pullen J, et al. Favorable prognosis associated with hyperdiploidy in children with acute lymphocytic leukemia correlates with extra chromosome 6 (A Pediatric Oncology Group study). Cancer. 1990;66:1183–1189
  37. Harris MB, Shuster JJ, Carroll A, et al. Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. Blood. 1992;3316–3324
  38. Ravindranath Y, Abella E, Krischer JP, et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML study 8498. Blood. 1992;80:2210–2214
  39. Link M, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314:1600–1602
  40. Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med. 1993;328:1725–1731
  41. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14:18–24
  42. Grier HE, Krailo MD, Tarbell NJ, Link MP, et al. Addition of ifosfamide and etoposide to standard therapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348:694–701
  43. Ortega JA, Krailo MD, Haas JE, et al. Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin: a report from the Children's Cancer Study Group. J Clin Oncol. 1991;9:2167–2176
  44. Douglass EC, Reynolds M, Finegold M, et al. Cisplatin, vincristine and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1993;11:96–99
  45. Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 2000;18:2665–2675
  46. Nesbit ME, Sather H, Robison LL, et al. Sanctuary therapy: a randomized trial of 724 children with previously untreated acute lymphoblastic leukemia: a report from Children's Cancer Study Group. Cancer Res. 1982;42:674–680
  47. Nesbit ME, Sather HN, Robison LL, et al. Randomized study of 3 years versus 5 years of chemotherapy in childhood acute lymphoblastic leukemia. J Clin Oncol. 1983;1:308–316
  48. Gaynon PS, Trigg ME, Heerema NA, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia. 2000;14:2223–2233
  49. Bostrom BC, Sensel MG, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2003;101:3809–3817
  50. Gaynon PS, Bleyer WA, Steinherz PG, et al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol. 1990;18:273–279
  51. Evans AE, Jenkin RD, Sposto R, et al. The treatment of medulloblastoma (Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone). J Neurosurg. 1990;72:572–582
  52. Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with medulloblastoma with reduced-dose craniospinal radiation and adjuvant chemotherapy: a Children's Cancer Group study. J Clin Oncol. 1999;17:2127–2136
  53. Patte C, Auperin A, Gerrard M, Michon J, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109:2773–2780
  54. Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109:2736–2743
  55. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid (Children's Cancer Group). N Engl J Med. 1999;341:1165–1173
  56. Matthay KK, Sather HN, Seeger RC, et al. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol. 1989;7:236–244
  57. Nesbit M, Buckley L, Lampkin B, et al. Comparison of allogeneic bone marrow transplantation (BMT) with maintenance chemotherapy in previously untreated childhood acute nonlymphocytic leukemia (ANLL). [abstract] Proc Am Soc Clin Oncol. 1987;6:163
  58. Woods WG, Ruymann FB, Lampkin BC, et al. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia. Cancer. 1990;66:1106–1113
  59. Hilden JM, Dinndorf PA, Meerbaum SO, et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood. 2006;108:441–451
  60. Neglia JP, Meadows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;325:1330–1336
  61. Bleyer WE, Fallavollita J, Robison L, et al. Influence of age, sex, and concurrent intrathecal methotrexate therapy on intellectual function after cranial irradiation during childhood: a report from the Children's Cancer Study Group. Pediatr Hematol Oncol. 1990;7:329–338
  62. Borowitz M, Devidas M, Bowman WP, et al. Prognostic significance of minimal residual disease (MRD) in childhood precursor ALL and its relation to other risk factors (A Children's Oncology Group (COG)). Blood. 2006;108:219
  63. Bhojwani D, Kang H, Moskowitz NP, et al. Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Blood. 2006;108:711–717
  64. Reaman GH, Haase GM. Quality of life research in childhood cancer (The time is now). Cancer. 1996;78:1330–1332
  65. Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2002;99:1986–1994
  66. Hammond GD, Nixon DW, Nachman JB, et al. American Cancer Society Workshop on Adolescents and Young Adults with Cancer (Workgroup #4: Clinical research implications). Cancer. 1993;71:2423

 Supported in part by CA 98543, CA98413, and the National Childhood Cancer Foundation.

PII: S0093-7754(08)00170-X

doi: 10.1053/j.seminoncol.2008.07.008

Seminars in Oncology
Volume 35, Issue 5 , Pages 484-493 , October 2008

Article Tools

* Image Usage & Resolution